Insurance Coverage Criteria for Repatha (Evolocumab)
Most insurances require patients to be on maximally tolerated statin therapy with LDL cholesterol ≥70 mg/dL, plus either ezetimibe failure or documented atherosclerotic cardiovascular disease (ASCVD), before approving Repatha coverage.
Primary Coverage Requirements
The core criteria that most insurance plans mandate include:
1. Baseline Statin Therapy Requirement
- Patients must be on maximally tolerated high-intensity statin therapy (such as atorvastatin ≥40 mg or rosuvastatin ≥20 mg daily) 1, 2
- Documentation of statin intolerance is acceptable if patients cannot tolerate any statin regimen 1
- Two-thirds of patients in the FOURIER trial were on high-intensity statins when evolocumab was added 2
2. Inadequate LDL-C Control
- LDL cholesterol must remain ≥70 mg/dL despite maximally tolerated statin therapy 2
- For very high-risk patients with recurrent events, some insurers may require failure to achieve LDL-C <55 mg/dL or even <40 mg/dL targets 1
- The FOURIER trial enrolled patients with LDL ≥70 mg/dL or non-HDL ≥100 mg/dL on background statin therapy 2
3. Sequential Therapy Documentation
- Ezetimibe must be tried first and documented as inadequate before PCSK9 inhibitor approval 1
- Guidelines recommend combination with ezetimibe as second-line therapy when statin goals are not met 1
- This stepwise approach reflects both clinical guidelines and cost considerations, as ezetimibe is significantly less expensive 2
4. Cardiovascular Disease Status
Insurance typically covers Repatha for one of these indications:
- Established ASCVD (prior myocardial infarction, stroke, or coronary revascularization) with residual hypercholesterolemia 2, 3, 2
- Heterozygous familial hypercholesterolemia (HeFH) requiring additional LDL-C lowering 2, 4
- Homozygous familial hypercholesterolemia (HoFH) 5, 4
- Very high-risk patients who experienced a second vascular event within 2 years while on maximally tolerated statin therapy 1
Common Pitfalls in Prior Authorization
Documentation Failures
- Insufficient documentation of "maximally tolerated" statin dose—insurers need evidence that higher doses were attempted and caused side effects, or that current dose is the maximum FDA-approved 1, 2
- Missing ezetimibe trial documentation—must show patient tried ezetimibe for adequate duration (typically 6-12 weeks) with inadequate response 1
- Lack of recent lipid panel showing LDL ≥70 mg/dL on current therapy 2
Timing Issues
- Prior authorization submitted before completing the required ezetimibe trial period 1
- Inadequate time on maximally tolerated statin therapy before requesting PCSK9 inhibitor 1, 2
Special Considerations
Alternative Pathways
- Statin intolerance provides an alternative pathway—patients who cannot tolerate statins may receive approval for Repatha with ezetimibe alone 1
- Familial hypercholesterolemia diagnoses often have more lenient approval criteria given the genetic basis and extreme LDL elevations 5, 4
Cost-Effectiveness Arguments
- While PCSK9 inhibitor costs have decreased over time, insurers still preferentially approve ezetimibe first due to lower cost 2
- The FOURIER trial demonstrated 15% relative risk reduction in major cardiovascular events, which supports coverage for secondary prevention 3, 6
Not Indicated For
- Primary treatment of hypertriglyceridemia—PCSK9 inhibitors like evolocumab are not recommended for this indication 5
- Patients who have not attempted or failed standard lipid-lowering therapy 1, 2
Practical Documentation Checklist
To maximize approval likelihood, submit: